What Are Peptides? A Women's Health Guide

What Exactly Is a Peptide?

A peptide is a molecule made of amino acids linked by peptide bonds, shorter than a full protein but longer than a single amino acid. The human body produces thousands of them. They function as hormones, neurotransmitters, and growth factors that regulate nearly every physiological system.

The Size Distinction

Proteins contain more than 50 amino acids. Peptides contain fewer. Insulin, at 51 amino acids, sits right at the boundary. This size matters because smaller peptides can often be absorbed, synthesized, and cleared by the body more efficiently than larger proteins. The National Institutes of Health classifies bioactive peptides as molecules that exert a biological effect beyond basic nutrition [1].

How Peptides Signal Cells

Peptides bind to specific receptors on cell surfaces, triggering intracellular cascades. GLP-1 (glucagon-like peptide-1), for instance, binds to receptors on pancreatic beta cells to stimulate insulin secretion and on hypothalamic neurons to reduce appetite. The receptor specificity of peptides makes them attractive drug targets because they can be designed to activate one pathway without broadly affecting others [2].

Your body naturally produces peptides like oxytocin (9 amino acids), endorphins (16 to 31 amino acids), and GnRH (10 amino acids). Pharmaceutical peptides mimic or modify these natural molecules.

GLP-1 Peptides: The Weight Loss Category

GLP-1 receptor agonists are the most prescribed peptide class in women's health today. They replicate and extend the action of the natural GLP-1 hormone your gut releases after eating.

Semaglutide

In the STEP-1 trial (N=1,961), participants receiving semaglutide 2.4 mg weekly achieved 14.9% mean body weight loss at 68 weeks compared with 2.4% in the placebo group [3]. Women made up approximately 74% of that trial population. The STEP-5 extension study showed weight loss maintained at 15.2% through 104 weeks with continued treatment [4].

Liraglutide

Liraglutide 3.0 mg (Saxenda) was the first GLP-1 approved for chronic weight management. The SCALE Obesity and Prediabetes trial (N=3,731) demonstrated 8.0% mean weight loss at 56 weeks versus 2.6% for placebo [5]. Generic liraglutide became available in 2024, reducing monthly costs from roughly $1,400 to $25, $200 depending on pharmacy and insurance.

Tirzepatide

Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist. It is technically a peptide of 39 amino acids. In SURMOUNT-1 (N=2,539), the 15 mg dose produced 22.5% body weight reduction at 72 weeks [6]. Women represented about 67% of participants. The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity lists both semaglutide and tirzepatide as first-line options for adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities [7].

GLP-1 Considerations Specific to Women

GLP-1 receptor agonists can reduce the efficacy of oral contraceptives by slowing gastric emptying. The FDA prescribing information for semaglutide advises patients using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after initiation and after each dose escalation [8]. This applies to all GLP-1 agonists, not just semaglutide.

Peptides for Bone Health in Women

Osteoporosis affects approximately 19.6% of women aged 50 and older in the United States, according to CDC data from NHANES [9]. Two FDA-approved peptide therapies target bone formation directly.

Teriparatide (Forteo)

Teriparatide is a 34-amino-acid fragment of parathyroid hormone. The Fracture Prevention Trial enrolled 1,637 postmenopausal women with prior vertebral fractures. Over a median of 19 months, teriparatide 20 mcg/day reduced new vertebral fractures by 65% and non-vertebral fractures by 53% compared with placebo [10]. The Endocrine Society's 2020 guidelines recommend teriparatide as initial therapy for postmenopausal women at very high fracture risk [11].

Abaloparatide (Tymlos)

Abaloparatide is a 34-amino-acid analog of parathyroid hormone-related protein. The ACTIVE trial (N=2,463) showed an 86% reduction in new vertebral fractures over 18 months versus placebo in postmenopausal women [12]. Both teriparatide and abaloparatide carry a boxed warning limiting use to 2 years based on osteosarcoma findings in rat studies, though no causal link has been confirmed in humans.

Peptides for Sexual Health

Bremelanotide (Vyleesi) is a cyclic 7-amino-acid peptide that activates melanocortin-4 receptors in the central nervous system. The FDA approved it in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women.

Clinical Evidence

In two Phase III trials (RECONNECT, total N=1,247), bremelanotide 1.75 mg subcutaneous injection increased the number of satisfying sexual events by approximately 0.5 per month over placebo, with statistically significant improvements in sexual desire scores on the Female Sexual Function Index [13]. Dr. Anita Clayton, who served as a principal investigator for the RECONNECT trials, stated: "Bremelanotide addresses a neurobiological component of desire that behavioral interventions alone may not reach" [14].

Not every woman with low desire has HSDD. The diagnosis requires personal distress about the condition, not simply a discrepancy between partners. Bremelanotide is administered as-needed, not daily, which distinguishes it from flibanserin (Addyi), the oral daily alternative.

Collagen Peptides and Skin Health

Collagen peptides (also called collagen hydrolysates) are the most commercially available peptide supplements. They are derived from bovine, marine, or porcine collagen broken down into fragments of 2 to 20 amino acids.

What the Evidence Shows

A systematic review of 19 randomized controlled trials published in the International Journal of Dermatology found that oral collagen peptide supplementation at doses of 2.5 to 15 g/day improved skin hydration, elasticity, and wrinkle depth over 4 to 24 weeks [15]. One double-blind trial (N=69) reported a 25% improvement in skin elasticity after 8 weeks of 2.5 g/day collagen peptide intake compared with placebo.

Limitations

Collagen peptides are classified as dietary supplements, not drugs. The FDA does not evaluate their efficacy claims before they reach shelves. Absorption mechanisms remain debated: whether ingested collagen fragments reach dermal fibroblasts intact or simply provide amino acid building blocks is still under investigation [16].

Investigational and Compounded Peptides

A growing number of peptides marketed to women have no FDA approval and limited or no Phase III human trial data.

BPC-157

Body Protection Compound-157 is a 15-amino-acid synthetic peptide derived from gastric juice proteins. Animal studies show accelerated tendon, ligament, and gut mucosal healing. A 2022 review in the Journal of Physiology summarized the preclinical evidence as promising but noted zero completed randomized controlled trials in humans [17]. No dosing standard exists.

GHK-Cu

Glycyl-L-histidyl-L-lysine copper complex is a naturally occurring tripeptide that declines with age. In vitro studies demonstrate stimulation of collagen synthesis and anti-inflammatory gene expression [18]. Topical formulations have shown modest wound-healing benefits in small human studies, but injectable GHK-Cu products sold through compounding pharmacies lack Phase III safety data.

Thymosin Beta-4 (TB-500)

This 43-amino-acid peptide promotes cell migration and tissue repair in animal models. It is not FDA-approved for any indication. The World Anti-Doping Agency lists it as a prohibited substance [19].

The Compounding Problem

The FDA has increased enforcement against compounding pharmacies producing copies of FDA-approved peptides. In October 2024, the FDA determined that the shortage of tirzepatide had ended, triggering restrictions on 503A and 503B compounders producing tirzepatide copies [20]. Compounded peptides are not subject to the same manufacturing standards (current Good Manufacturing Practices) as FDA-approved drugs. Contamination, incorrect dosing, and degradation are documented risks.

Dr. Janet Woodcock, former FDA Principal Deputy Commissioner, noted in a 2024 agency communication: "Patients using compounded versions of GLP-1 drugs may be exposed to products that have not been tested for sterility, potency, or purity" [21].

Peptide Hormones Already in Your Body

Understanding endogenous peptides helps clarify why synthetic versions can be therapeutic. Several peptide hormones play outsize roles in women's physiology.

GnRH (Gonadotropin-Releasing Hormone)

This 10-amino-acid peptide controls the entire reproductive hormone cascade. Pulsatile GnRH release from the hypothalamus triggers LH and FSH secretion, which in turn drive estrogen and progesterone production. Synthetic GnRH agonists like leuprolide are used to treat endometriosis, uterine fibroids, and precocious puberty [22].

Oxytocin

A 9-amino-acid peptide produced in the hypothalamus. Beyond its well-known role in labor and lactation, oxytocin modulates stress response, social bonding, and pain perception. Research published in Psychoneuroendocrinology found that intranasal oxytocin reduced cortisol reactivity in women exposed to social stress, though clinical applications remain experimental [23].

Kisspeptin

A 54-amino-acid peptide that acts upstream of GnRH. Kisspeptin signaling is required for puberty onset and normal ovulation. Researchers at Imperial College London have studied kisspeptin-54 as a diagnostic and therapeutic tool for hypothalamic amenorrhea. A Phase II trial (N=30) showed that subcutaneous kisspeptin restored LH pulsatility in women with functional hypothalamic amenorrhea [24].

How to Evaluate a Peptide Therapy

Not all peptides carry equal evidence. A practical framework for assessment:

Check FDA approval status. If the peptide is FDA-approved for your condition, a regulatory body has reviewed Phase III trial data for safety and efficacy. If it is not approved, you are accepting a higher level of uncertainty.

Ask about the source. FDA-approved peptides from licensed manufacturers follow cGMP standards. Compounded peptides from 503A pharmacies do not require FDA pre-approval. Peptides purchased online from research chemical suppliers are intended for laboratory use, not human injection.

Look at trial size and design. A peptide with two randomized controlled trials enrolling over 1,000 participants (like semaglutide or bremelanotide) provides far more confidence than one supported only by rodent models or case series of 10 to 20 people.

Assess sex-specific data. Many peptide trials enrolled predominantly male participants, particularly in the growth hormone secretagogue category. Ask whether the peptide has been studied in women at the dose being recommended.

Confirm monitoring protocols. Any peptide therapy should include baseline and follow-up lab work. For GLP-1 agonists, this means metabolic panels and lipid profiles. For teriparatide, calcium and vitamin D levels. For investigational peptides, the monitoring requirements are often undefined, which itself is a red flag.

Cost and Access Realities

The economics of peptide therapy vary enormously. FDA-approved GLP-1 agonists carry list prices exceeding $1,000/month without insurance, though manufacturer savings programs and generic liraglutide have expanded access. Teriparatide costs approximately $3,500/month at list price; a biosimilar (Teriparatide-rDNA, Teva) reduced this by roughly 30% [25].

Compounded peptides often cost $100, $400/month, which appears attractive until you factor in the absence of insurance coverage, uncertain quality, and zero liability if something goes wrong. The American Association of Clinical Endocrinology (AACE) recommends FDA-approved therapies as first-line when available and states that compounded alternatives should be reserved for documented shortages or true medical necessity, such as allergy to an inactive ingredient [26].

What Women Should Ask Their Clinician

Before starting any peptide therapy, five questions produce better outcomes than passive acceptance:

1. Is this peptide FDA-approved for my specific condition?
2. What is the largest human trial supporting this dose in women?
3. What lab work do I need before starting and during treatment?
4. How will we measure whether this is working, and on what timeline?
5. What happens when I stop?

That last question matters more than most patients realize. Teriparatide's bone-building effects require transition to an antiresorptive agent (like a bisphosphonate or denosumab) after discontinuation, or bone density gains reverse within 12 to 18 months [27]. GLP-1 agonists show significant weight regain after cessation: the STEP-1 extension trial found participants regained two-thirds of lost weight within one year of stopping semaglutide [28].